Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
20
PRFX Quote, Financials, Valuation and Earnings
Last price:
$2.11
Seasonality move
:
-22.91%
Day range:
$2.04 - $2.12
52-week range:
$1.80 - $17.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
77.53x
P/B ratio:
1.73x
Volume:
6.5K
Avg. volume:
34.2K
1-year change:
-81.74%
Market cap:
$1.6M
Revenue:
$17K
EPS (TTM):
-$8.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRFX
PRF Technologies Ltd.
|
-- | -- | -- | -- | -- |
|
BLRX
BioLineRx Ltd.
|
$343K | -$1.04 | 35.2% | -49.07% | $20.33 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$1.2M | -$0.08 | -46.52% | -2.83% | $5.80 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.65 | 316.67% | -79.86% | $12.00 |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRFX
PRF Technologies Ltd.
|
$2.10 | -- | $1.6M | -- | $0.00 | 0% | 77.53x |
|
BLRX
BioLineRx Ltd.
|
$2.21 | $20.33 | $10M | -- | $0.00 | 0% | 7.60x |
|
CANF
Can-Fite BioPharma Ltd.
|
$3.07 | $2.50 | $4.1M | -- | $0.00 | 0% | 7.14x |
|
CGEN
Compugen Ltd.
|
$2.26 | $5.80 | $220M | 6.30x | $0.00 | 0% | 2.99x |
|
PLUR
Pluri, Inc.
|
$3.32 | $12.00 | $33.4M | -- | $0.00 | 0% | 20.28x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
$2.43 | -- | $5.7M | -- | $0.00 | 0% | 34.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRFX
PRF Technologies Ltd.
|
-- | 0.711 | -- | -- |
|
BLRX
BioLineRx Ltd.
|
35.81% | 3.203 | 59% | 1.73x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 2.389 | -- | -- |
|
CGEN
Compugen Ltd.
|
2.8% | -0.650 | 2.05% | 6.45x |
|
PLUR
Pluri, Inc.
|
172.93% | -0.001 | 98.32% | 0.40x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
2.86% | 0.921 | 1.28% | 0.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRFX
PRF Technologies Ltd.
|
-- | -$7.3M | -- | -- | -- | -$5M |
|
BLRX
BioLineRx Ltd.
|
$91.6K | -$3.4M | -6.72% | -11.07% | -1745.49% | -$3.3M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$63.8M | $56M | 54.64% | 57.22% | 83.23% | -- |
|
PLUR
Pluri, Inc.
|
-$43K | -$6.5M | -93.31% | -5662.45% | -3285.86% | -$5.7M |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -$764K | -33.97% | -34.34% | -283.95% | -- |
PRF Technologies Ltd. vs. Competitors
-
Which has Higher Returns PRFX or BLRX?
BioLineRx Ltd. has a net margin of -- compared to PRF Technologies Ltd.'s net margin of -1152.66%. PRF Technologies Ltd.'s return on equity of -- beat BioLineRx Ltd.'s return on equity of -11.07%.
Company Gross Margin Earnings Per Share Invested Capital PRFXPRF Technologies Ltd.-- -$50.60 -- BLRXBioLineRx Ltd.46.93% -$0.32 $33.5M -
What do Analysts Say About PRFX or BLRX?
PRF Technologies Ltd. has a consensus price target of --, signalling upside risk potential of 11328.57%. On the other hand BioLineRx Ltd. has an analysts' consensus of $20.33 which suggests that it could grow by 820.06%. Given that PRF Technologies Ltd. has higher upside potential than BioLineRx Ltd., analysts believe PRF Technologies Ltd. is more attractive than BioLineRx Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PRFXPRF Technologies Ltd.0 0 0 BLRXBioLineRx Ltd.2 0 0 -
Is PRFX or BLRX More Risky?
PRF Technologies Ltd. has a beta of 0.712, which suggesting that the stock is 28.792% less volatile than S&P 500. In comparison BioLineRx Ltd. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.372%.
-
Which is a Better Dividend Stock PRFX or BLRX?
PRF Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLineRx Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PRF Technologies Ltd. pays -- of its earnings as a dividend. BioLineRx Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRFX or BLRX?
PRF Technologies Ltd. quarterly revenues are --, which are smaller than BioLineRx Ltd. quarterly revenues of $195.2K. PRF Technologies Ltd.'s net income of -$7.3M is lower than BioLineRx Ltd.'s net income of -$2.3M. Notably, PRF Technologies Ltd.'s price-to-earnings ratio is -- while BioLineRx Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PRF Technologies Ltd. is 77.53x versus 7.60x for BioLineRx Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRFXPRF Technologies Ltd.77.53x -- -- -$7.3M BLRXBioLineRx Ltd.7.60x -- $195.2K -$2.3M
-
Which has Higher Returns PRFX or CANF?
Can-Fite BioPharma Ltd. has a net margin of -- compared to PRF Technologies Ltd.'s net margin of --. PRF Technologies Ltd.'s return on equity of -- beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRFXPRF Technologies Ltd.-- -$50.60 -- CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About PRFX or CANF?
PRF Technologies Ltd. has a consensus price target of --, signalling upside risk potential of 11328.57%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1528.67%. Given that PRF Technologies Ltd. has higher upside potential than Can-Fite BioPharma Ltd., analysts believe PRF Technologies Ltd. is more attractive than Can-Fite BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PRFXPRF Technologies Ltd.0 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is PRFX or CANF More Risky?
PRF Technologies Ltd. has a beta of 0.712, which suggesting that the stock is 28.792% less volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 1.063, suggesting its more volatile than the S&P 500 by 6.323%.
-
Which is a Better Dividend Stock PRFX or CANF?
PRF Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PRF Technologies Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRFX or CANF?
PRF Technologies Ltd. quarterly revenues are --, which are smaller than Can-Fite BioPharma Ltd. quarterly revenues of --. PRF Technologies Ltd.'s net income of -$7.3M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, PRF Technologies Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PRF Technologies Ltd. is 77.53x versus 7.14x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRFXPRF Technologies Ltd.77.53x -- -- -$7.3M CANFCan-Fite BioPharma Ltd.7.14x -- -- --
-
Which has Higher Returns PRFX or CGEN?
Compugen Ltd. has a net margin of -- compared to PRF Technologies Ltd.'s net margin of 84.43%. PRF Technologies Ltd.'s return on equity of -- beat Compugen Ltd.'s return on equity of 57.22%.
Company Gross Margin Earnings Per Share Invested Capital PRFXPRF Technologies Ltd.-- -$50.60 -- CGENCompugen Ltd.94.75% $0.60 $105.7M -
What do Analysts Say About PRFX or CGEN?
PRF Technologies Ltd. has a consensus price target of --, signalling upside risk potential of 11328.57%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 156.64%. Given that PRF Technologies Ltd. has higher upside potential than Compugen Ltd., analysts believe PRF Technologies Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PRFXPRF Technologies Ltd.0 0 0 CGENCompugen Ltd.5 0 0 -
Is PRFX or CGEN More Risky?
PRF Technologies Ltd. has a beta of 0.712, which suggesting that the stock is 28.792% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.766, suggesting its more volatile than the S&P 500 by 176.625%.
-
Which is a Better Dividend Stock PRFX or CGEN?
PRF Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PRF Technologies Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRFX or CGEN?
PRF Technologies Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $67.3M. PRF Technologies Ltd.'s net income of -$7.3M is lower than Compugen Ltd.'s net income of $56.8M. Notably, PRF Technologies Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 6.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PRF Technologies Ltd. is 77.53x versus 2.99x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRFXPRF Technologies Ltd.77.53x -- -- -$7.3M CGENCompugen Ltd.2.99x 6.30x $67.3M $56.8M
-
Which has Higher Returns PRFX or PLUR?
Pluri, Inc. has a net margin of -- compared to PRF Technologies Ltd.'s net margin of -3470.71%. PRF Technologies Ltd.'s return on equity of -- beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital PRFXPRF Technologies Ltd.-- -$50.60 -- PLURPluri, Inc.-21.72% -$0.71 $25.4M -
What do Analysts Say About PRFX or PLUR?
PRF Technologies Ltd. has a consensus price target of --, signalling upside risk potential of 11328.57%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 261.45%. Given that PRF Technologies Ltd. has higher upside potential than Pluri, Inc., analysts believe PRF Technologies Ltd. is more attractive than Pluri, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRFXPRF Technologies Ltd.0 0 0 PLURPluri, Inc.1 0 0 -
Is PRFX or PLUR More Risky?
PRF Technologies Ltd. has a beta of 0.712, which suggesting that the stock is 28.792% less volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.767%.
-
Which is a Better Dividend Stock PRFX or PLUR?
PRF Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PRF Technologies Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRFX or PLUR?
PRF Technologies Ltd. quarterly revenues are --, which are smaller than Pluri, Inc. quarterly revenues of $198K. PRF Technologies Ltd.'s net income of -$7.3M is lower than Pluri, Inc.'s net income of -$6.9M. Notably, PRF Technologies Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PRF Technologies Ltd. is 77.53x versus 20.28x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRFXPRF Technologies Ltd.77.53x -- -- -$7.3M PLURPluri, Inc.20.28x -- $198K -$6.9M
-
Which has Higher Returns PRFX or XTLB?
XTL Biopharmaceuticals Ltd. has a net margin of -- compared to PRF Technologies Ltd.'s net margin of -341.36%. PRF Technologies Ltd.'s return on equity of -- beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.
Company Gross Margin Earnings Per Share Invested Capital PRFXPRF Technologies Ltd.-- -$50.60 -- XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M -
What do Analysts Say About PRFX or XTLB?
PRF Technologies Ltd. has a consensus price target of --, signalling upside risk potential of 11328.57%. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 5048.45%. Given that PRF Technologies Ltd. has higher upside potential than XTL Biopharmaceuticals Ltd., analysts believe PRF Technologies Ltd. is more attractive than XTL Biopharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PRFXPRF Technologies Ltd.0 0 0 XTLBXTL Biopharmaceuticals Ltd.0 0 0 -
Is PRFX or XTLB More Risky?
PRF Technologies Ltd. has a beta of 0.712, which suggesting that the stock is 28.792% less volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.270, suggesting its more volatile than the S&P 500 by 27.027%.
-
Which is a Better Dividend Stock PRFX or XTLB?
PRF Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PRF Technologies Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRFX or XTLB?
PRF Technologies Ltd. quarterly revenues are --, which are smaller than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. PRF Technologies Ltd.'s net income of -$7.3M is lower than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, PRF Technologies Ltd.'s price-to-earnings ratio is -- while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PRF Technologies Ltd. is 77.53x versus 34.33x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRFXPRF Technologies Ltd.77.53x -- -- -$7.3M XTLBXTL Biopharmaceuticals Ltd.34.33x -- $162K -$553K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
